Apellis Pharmaceuticals, Inc

(NASDAQ:APLS)

Latest On Apellis Pharmaceuticals, Inc (APLS):

Date/Time Type Description Signal Details
2023-05-25 17:48 ESTNewsApellis and Sobi to drop ALS candidate on Phase 2 setbackN/A
2023-05-18 17:01 ESTNewsApellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition SpaceN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74MN/A
2023-05-03 20:58 ESTNewsApellis Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-05-01 19:14 ESTNewsApellis weakness on Iveric Bio takeout is buying opportunity - analystN/A
2023-05-01 06:55 ESTNewsApellis Pharmaceuticals (APLS) Presents at the Association for Research in Vision and Ophthalmology Annual Meeting - SlideshowN/A
2023-04-03 17:26 ESTNewsApellis Pharmaceuticals may be worth $90-$100 a share in sale - analystN/A
2023-04-02 23:22 ESTNewsApellis Pharmaceuticals sees takeover interest from large pharma - BloombergN/A
2023-03-24 22:48 ESTNewsApellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy MarketN/A
2023-03-16 14:19 ESTNewsApellis Pharmaceuticals' Empaveli sNDA action date extended by FDAN/A
2023-02-23 11:44 ESTNewsApellis Pharmaceuticals prices $350M in stock offeringN/A
2023-02-22 09:58 ESTNewsApellis Pharmaceuticals to raise $300M in stock and warrants offeringN/A
2023-02-21 21:29 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86MN/A
2023-02-18 02:43 ESTNewsApellis wins FDA nod for eye disorder therapyN/A
2023-01-27 18:43 ESTNewsApellis: Empaveli Ought To Win Approval For Eye Disease In February - The Future Looks BrightN/A
2023-01-21 14:26 ESTNewsStocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A WildcardsN/A
2023-01-05 20:02 ESTNewsApellis appoints Baumal as Chief Medical OfficerN/A
2023-01-04 02:30 ESTNewsApellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech previewN/A
2022-12-15 23:44 ESTNewsApellis Pharmaceuticals: Approval Is Baked Into ValuationN/A
2022-11-18 10:24 ESTNewsApellis surges 17% as FDA accepts to review new data in filing for eye disorder drugN/A
2022-11-11 06:07 ESTNewsApellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA marketN/A
2022-11-08 08:01 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46MN/A
2022-11-08 08:00 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call TranscriptN/A
2022-11-05 08:22 ESTNewsApellis Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-11-03 23:08 ESTNewsApellis sinks 20% as FDA review period for eye disease drug extendsN/A
2022-10-16 23:00 ESTNewsCiti lists four more value-creating events in biotech for this yearN/A
2022-09-29 06:33 ESTNewsApellis Pharmaceuticals: Trying To Develop A Blockbuster FranchiseN/A
2022-09-08 07:22 ESTNewsApellis gains as FDA says AdCom unnecessary for eye disease candidateN/A
2022-08-24 16:51 ESTNewsApellis stock dips amid 2-year data of pegcetacoplan for eye disorderN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 18:56 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63MN/A
2022-08-06 06:05 ESTNewsApellis Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-27 15:50 ESTNewsApellis to exchange $75.6M in convertible senior notes for common stockN/A
2022-07-20 18:36 ESTNewsApellis Pharmaceuticals: The Meaning Of Priority Review For Pegcetacoplan For Geographic AtrophyN/A
2022-07-20 03:57 ESTNewsWainwright sees blockbuster potential for Apellis eye degeneration therapy; shares up 22%N/A
2022-07-19 13:21 ESTNewsApellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorderN/A
2022-07-19 13:19 ESTNewsH.C. Wainwright sees blockbuster potential for Apellis' treatment in eye degenerationN/A
2022-06-25 15:25 ESTNewsApellis: Mixed Data, But Definitely Approvable In GAN/A
2022-06-13 19:55 ESTNewsHot Stocks: APLS & SKIL both gain, TSLA declined despite upgrade, and VLTA plungedN/A
2022-06-10 11:34 ESTNewsApellis/Sobi Empaveli shows benefit in rare blood disorder patients in new analysesN/A
2022-06-01 11:05 ESTNewsApellis files for FDA approval of pegcetacoplan to treat eye disorderN/A
2022-05-06 19:17 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-06 19:15 ESTNewsApellis Pharmaceuticals (APLS) Investor Presentation - SlideshowN/A
2022-05-04 22:43 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52MN/A
2022-05-04 22:42 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 03:15 ESTNewsApellis Pharmaceuticals Q1 2022 Earnings PreviewN/A

About Apellis Pharmaceuticals, Inc (APLS):

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Apellis Pharmaceuticals, Inc
  • Symbol APLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 374
  • Fiscal Year EndDecember
  • IPO Date2017-11-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.apellis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 13.99
  • Price/Book (Most Recent Quarter) 18.33
  • Enterprise Value Revenue 12.97
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$6.46
  • Next Year EPS Estimate -$5.31
  • Next Quarter EPS Estimate -$1.60
  • Profit Margin -138%
  • Operating Margin -85%
  • Return on Assets -20%
  • Return on Equity -289%
  • Revenue 250.65 million
  • Earnings Per Share -$3.32
  • Revenue Per Share $3.34
  • Gross Profit -74325000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 3.54 billion
  • Analyst Target Price $64.14
  • Book Value Per Share $2.69
View More

Share Statistics

  • Shares Outstanding 80.38 million
  • Shares Float 59.7 million
  • % Held by Insiders 2117%
  • % Held by Institutions 82.85%
  • Shares Short 8.11 million
  • Shares Short Prior Month 7.75 million
  • Short Ratio 13.44
  • Short % of Float 15%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.52
  • 52 Week High $58.47
  • 52 Week Low $21.84
  • 50 Day Moving Average 46.47
  • 200 Day Moving Average 42.62
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Apellis Pharmaceuticals, Inc (APLS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Apellis Pharmaceuticals, Inc (APLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.93-$0.45304.58%
2020-09-302020-11-02$646000-$1.79-$1.58-13.31%
2020-06-302020-07-30$N/A-$1.57-$1.34-17.56%
2020-03-312020-04-29$N/A-$2.29-$1.39-64.72%
2019-12-312020-02-27$N/A-$1.77-$1.14-55%
2019-09-302019-11-05$N/A-$1.10-$1.03-6.44%
2019-06-302019-07-31$N/A-$1.12-$0.78-44.39%
2019-03-312019-05-07$N/A-$0.87-$0.68-27.49%
2018-12-312019-02-26$N/A-$0.65-$0.707.58%
2018-09-302018-11-13$N/A-$0.64-$0.697.02%
2018-06-302018-07-31$N/A-$0.61-$0.42-45.86%
2018-03-312018-04-30$N/A-$0.43-$0.27-57.28%
2017-12-312018-03-19$N/A-$0.61-$0.27-129.32%
2017-09-302017-12-20$N/A-$0.23-$0.242.75%

Apellis Pharmaceuticals, Inc (APLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Apellis Pharmaceuticals, Inc (APLS) Chart:

Apellis Pharmaceuticals, Inc (APLS) News:

Below you will find a list of latest news for Apellis Pharmaceuticals, Inc (APLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Apellis Pharmaceuticals, Inc (APLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-18340CALL0 00FALSE00
2026-06-18360CALL0 00FALSE00
2026-06-18370CALL0 00FALSE00
2026-06-18380CALL0 00FALSE00
2026-06-18390CALL0 00FALSE00
2026-06-18430CALL0 08.52FALSE00
2026-06-18440CALL0 011.97FALSE00
2026-06-18460CALL0 018.21FALSE00
2026-06-18470CALL0 021.1FALSE00
2026-06-18480CALL0 023.87FALSE00
2026-06-18490CALL0 026.53FALSE00
2026-06-18330PUT0 033.53TRUE00
2026-06-18340PUT0 076.35TRUE00
2026-06-18360PUT0 061.72TRUE00
2026-06-18380.06PUT0 6014.16TRUE00
2026-06-18430PUT0 022.9TRUE00
2026-06-18460PUT0 035.32TRUE00
2026-06-18480PUT0 045.42TRUE00
2026-06-18490PUT0 049.4TRUE00
2026-07-17100CALL0 0150.51FALSE00
2026-07-17120CALL0 2127.13FALSE00
2026-07-17130CALL0 1116.7FALSE00
2026-07-17140CALL0 0106.83FALSE00
2026-07-17150CALL0 097.33FALSE00
2026-07-17160CALL0 087.92FALSE00
2026-07-17170CALL0 178.03FALSE00
2026-07-17180CALL0 00FALSE00
2026-07-17190CALL0 00FALSE00
2026-07-17200CALL0 360FALSE00
2026-06-182120.08CALL1 40FALSE00
2026-07-17220CALL0 10FALSE00
2026-07-17230CALL0 270FALSE00
2026-07-17240CALL0 60FALSE00
2026-07-17250CALL0 80FALSE00
2026-06-182615CALL14 180FALSE00
2026-07-17270CALL0 00FALSE00
2026-07-17280CALL0 420FALSE00
2026-07-17290CALL0 00FALSE00
2026-07-17300CALL0 60FALSE00
2026-07-17310CALL0 10FALSE00
2026-07-17320CALL0 10FALSE00
2026-07-17330CALL0 20FALSE00
2026-07-17340CALL0 00FALSE00
2026-07-17350CALL0 30FALSE00
2026-07-17360CALL0 00FALSE00
2026-07-17370CALL0 00FALSE00
2026-07-17380CALL0 00FALSE00
2026-07-17390CALL0 00FALSE00
2026-07-17401.05CALL0 5770FALSE00
2026-07-17410.05CALL0 48630FALSE00
2026-07-17420CALL0 13.09FALSE00
2026-07-17430CALL0 16FALSE00
2026-07-17440CALL0 030.26FALSE00
2026-07-17450CALL0 034.61FALSE00
2026-07-17460CALL0 038.64FALSE00
2026-07-17470CALL0 042.42FALSE00
2026-07-17480CALL0 045.98FALSE00
2026-07-17490CALL0 019.46FALSE00
2026-07-17500CALL0 021.38FALSE00
2026-07-17550CALL0 030.09FALSE00
2026-07-17600CALL0 137.7FALSE00
2026-07-17100PUT0 0136.22TRUE00
2026-07-17120PUT0 0237.93TRUE00
2026-07-17130PUT0 1111.83TRUE00
2026-07-17140PUT0 3104.99TRUE00
2026-07-17150PUT0 198.63TRUE00
2026-07-17160PUT0 192.69TRUE00
2026-07-17170PUT0 187.12TRUE00
2026-07-17180PUT0 381.86TRUE00
2026-07-17190PUT0 1276.9TRUE00
2026-06-18200.05PUT1 660.5TRUE00
2026-07-17210PUT0 1967.69TRUE00
2026-07-17220PUT0 3563.4TRUE00
2026-07-17230PUT0 10459.3TRUE00
2026-07-17240PUT0 4360.85TRUE00
2026-07-17250PUT0 17460.41TRUE00
2026-06-18260.03PUT5 70.25TRUE00
2026-07-17270PUT0 054.84TRUE00
2026-07-17280PUT0 750.78TRUE00
2026-06-18290.05PUT2 10.25TRUE00
2026-07-17300.05PUT0 228734.43TRUE00
2026-07-17310PUT0 1042.56TRUE00
2026-07-17320PUT0 240.01TRUE00
2026-07-17330PUT0 525.22TRUE00
2026-07-17340PUT0 122.28TRUE00
2026-07-17350.05PUT0 43819.38TRUE00
2026-07-17360PUT0 3216.52TRUE00
2026-07-17370PUT0 7013.68TRUE00
2026-07-17380PUT0 510.84TRUE00
2026-06-18390PUT0 039.35TRUE00
2026-07-17400.03PUT0 4245.18TRUE00
2026-07-17410.04PUT0 3071.68TRUE00
2026-07-17420PUT0 025.51TRUE00
2026-07-17430PUT0 018.1TRUE00
2026-07-17440PUT0 021.47TRUE00
2026-06-18450PUT0 030.75TRUE00
2026-07-17460PUT0 028.93TRUE00
2026-07-17470PUT0 033.46TRUE00
2026-07-17480PUT0 036.72TRUE00
2026-07-17490PUT0 039.83TRUE00
2026-07-17500PUT0 041.52TRUE00
2026-07-17550PUT0 054.68TRUE00
2026-07-17600PUT0 066TRUE00
2026-10-16100CALL0 0108.8FALSE00
2026-10-16120CALL0 097.8FALSE00
2026-10-16130CALL0 089.97FALSE00
2026-10-16140CALL0 082.67FALSE00
2026-10-16150CALL0 075.77FALSE00
2026-10-16160CALL0 075.24FALSE00
2026-10-16170CALL0 069.25FALSE00
2026-10-16180CALL0 00FALSE00
2026-10-16190CALL0 058.03FALSE00
2026-10-16200CALL0 452.65FALSE00
2026-10-16210CALL0 047.27FALSE00
2026-10-16220CALL0 048.44FALSE00
2026-10-16230CALL0 043.83FALSE00
2026-06-182416.93CALL1 60FALSE00
2026-10-16250CALL0 00FALSE00
2026-10-16260CALL0 00FALSE00
2026-10-16270CALL0 00FALSE00
2026-10-16280CALL0 120FALSE00
2026-10-16290CALL0 10FALSE00
2026-10-16300CALL0 10FALSE00
2026-10-16310CALL0 00FALSE00
2026-10-16320CALL0 00FALSE00
2026-10-16330CALL0 00FALSE00
2026-10-16340CALL0 00FALSE00
2026-10-16350CALL0 10FALSE00
2026-10-16360CALL0 00FALSE00
2026-10-16370CALL0 00FALSE00
2026-10-16380CALL0 00FALSE00
2026-10-16390CALL0 00FALSE00
2026-10-16401.1CALL0 720FALSE00
2026-06-18410.05CALL0 830FALSE00
2026-10-16420.05CALL0 191.15FALSE00
2026-10-16430CALL0 03.16FALSE00
2026-10-16440CALL0 04.89FALSE00
2026-10-16450CALL0 06.47FALSE00
2026-10-16460CALL0 07.95FALSE00
2026-10-16470CALL0 09.36FALSE00
2026-10-16480CALL0 010.7FALSE00
2026-10-16490CALL0 011.99FALSE00
2026-10-16500CALL0 013.24FALSE00
2026-10-16550CALL0 018.89FALSE00
2026-10-16600CALL0 023.82FALSE00
2026-10-16100PUT0 088.46TRUE00
2026-10-16120PUT0 0154.56TRUE00
2026-10-16130PUT0 072.71TRUE00
2026-10-16140PUT0 0136.81TRUE00
2026-10-16150PUT0 464.18TRUE00
2026-10-16160PUT0 0121.77TRUE00
2026-10-16170PUT0 556.75TRUE00
2026-10-16180PUT0 058.38TRUE00
2026-10-16190PUT0 354.9TRUE00
2026-10-16200PUT0 051.61TRUE00
2026-10-16210PUT0 148.47TRUE00
2026-10-16220PUT0 045.47TRUE00
2026-10-16230PUT0 338.79TRUE00
2026-10-16240PUT0 077.18TRUE00
2026-10-16250PUT0 4133.81TRUE00
2026-10-16260PUT0 038.72TRUE00
2026-10-16270PUT0 037.5TRUE00
2026-10-16280PUT0 026.97TRUE00
2026-10-16290PUT0 056.29TRUE00
2026-10-16300PUT0 922.76TRUE00
2026-10-16310PUT0 048.75TRUE00
2026-10-16320PUT0 045.1TRUE00
2026-10-16330PUT0 041.52TRUE00
2026-10-16340PUT0 037.98TRUE00
2026-10-16350.05PUT0 18113.07TRUE00
2026-10-16360PUT0 016.63TRUE00
2026-10-16370PUT0 09.41TRUE00
2026-10-16380PUT0 012.23TRUE00
2026-10-16390PUT0 05.73TRUE00
2026-10-16400.05PUT0 5364.48TRUE00
2026-06-18410.05PUT0 352.05TRUE00
2026-10-16420PUT0 018.02TRUE00
2026-10-16430PUT0 013.18TRUE00
2026-06-18440PUT0 027.2TRUE00
2026-10-16450PUT0 018.63TRUE00
2026-10-16460PUT0 021.16TRUE00
2026-10-16470PUT0 024.23TRUE00
2026-10-16480PUT0 026.51TRUE00
2026-10-16490PUT0 028.69TRUE00
2026-10-16500PUT0 029.99TRUE00
2026-10-16550PUT0 038.25TRUE00
2026-10-16600PUT0 047.12TRUE00
2027-01-1550CALL0 00FALSE00
2027-01-15100CALL0 170FALSE00
2027-01-15130CALL0 00FALSE00
2026-06-181525.8CALL300 3780FALSE00
2027-01-15180CALL0 10FALSE00
2027-01-152020.8CALL0 480FALSE00
2026-06-182317.8CALL30 510FALSE00
2026-06-182516.04CALL1 70FALSE00
2026-06-182812.83CALL50 420FALSE00
2027-01-153011.4CALL0 2020FALSE00
2026-06-18330CALL0 00FALSE00
2027-01-15356.3CALL0 25130FALSE00
2027-01-15370CALL0 10FALSE00
2027-01-15401.05CALL0 13200FALSE00
2027-01-15420.05CALL0 33760FALSE00
2027-01-15450CALL0 494.62FALSE00
2027-01-15470CALL0 16.95FALSE00
2026-06-18500.01CALL1 500.13FALSE00
2027-01-15550CALL0 60914.58FALSE00
2027-01-15600CALL0 018.51FALSE00
2027-01-1550PUT0 0104.81TRUE00
2027-01-15100PUT0 770.73TRUE00
2027-01-15130PUT0 058.2TRUE00
2027-01-15150PUT0 38951.43TRUE00
2027-01-15180PUT0 1142.82TRUE00
2027-01-15200PUT0 19937.86TRUE00
2026-06-18230.05PUT1 20.5TRUE00
2026-06-18250.05PUT40 1740.5TRUE00
2027-01-15280PUT0 921.86TRUE00
2027-01-15300PUT0 64318.52TRUE00
2027-01-15330PUT0 513.81TRUE00
2027-01-15350PUT0 65010.83TRUE00
2027-01-15370.05PUT0 5927.93TRUE00
2027-01-15400.05PUT0 13944.05TRUE00
2027-01-15420PUT0 176.1TRUE00
2027-01-15450PUT0 013.3TRUE00
2026-06-18470PUT0 041.26TRUE00
2026-06-18509PUT1 0TRUE00
2027-01-15550PUT0 032.95TRUE00
2027-01-15600PUT0 038.73TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 00FALSE00
2026-06-181030.94CALL12 10FALSE00
2028-01-21130CALL0 30FALSE00
2028-01-21150CALL0 00FALSE00
2028-01-21180CALL0 10FALSE00
2026-06-182020.8CALL30 20FALSE00
2028-01-21220CALL0 00FALSE00
2028-01-21250CALL0 20FALSE00
2028-01-21270CALL0 20FALSE00
2026-06-183011.4CALL4 1910FALSE00
2026-06-18327.1CALL 60FALSE00
2026-06-18350CALL0 00FALSE00
2028-01-21370CALL0 00FALSE00
2026-06-18401.05CALL0 340FALSE00
2026-06-18420.05CALL0 244.67FALSE00
2026-06-18450.03CALL0 1015.68FALSE00
2028-01-21470CALL0 03.13FALSE00
2028-01-21500CALL0 05.18FALSE00
2028-01-21550CALL0 08.11FALSE00
2026-06-18600.1CALL 20.25FALSE00
2028-01-2130PUT0 084.15FALSE00
2028-01-2150PUT0 067.39TRUE00
2028-01-21100PUT0 045.79TRUE00
2028-01-21130PUT0 041.31TRUE00
2028-01-21150PUT0 2536.65TRUE00
2028-01-21180PUT0 2030.75TRUE00
2028-01-21200PUT0 024.98TRUE00
2028-01-21220PUT0 522.14TRUE00
2028-01-21250PUT0 018.31TRUE00
2028-01-21270PUT0 815.98TRUE00
2026-06-18300.05PUT2 22870.25TRUE00
2026-06-18320.1PUT2 110.25TRUE00
2026-06-18350PUT0 2625.68TRUE00
2026-06-18370PUT0 054.4TRUE00
2026-06-18400PUT0 06.24TRUE00
2026-06-18420PUT0 033.15TRUE00
2028-01-21450PUT0 00TRUE00
2028-01-21470PUT0 014.12TRUE00
2028-01-21500PUT0 017.93TRUE00
2026-06-185514PUT2 0TRUE00
2028-01-21600PUT0 028.02TRUE00

Latest APLS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$39.4
Jun 13, 2022 7:59 PM EST25$39.4
Jun 13, 2022 7:59 PM EST86$39.39
Jun 13, 2022 7:59 PM EST14$39.4
Jun 13, 2022 7:59 PM EST32$39.4

Apellis Pharmaceuticals, Inc (APLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000083423720004741/0000834237-20-004741-index.htm
2020-02-053/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320003295/0000899243-20-003295-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320008068/0000899243-20-008068-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027595/0000899243-20-027595-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027598/0000899243-20-027598-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090221920000352/0000902219-20-000352-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090266420001196/0000902664-20-001196-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000092963820000336/0000929638-20-000336-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013334/0001127602-20-013334-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013338/0001127602-20-013338-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-04-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014554/0001127602-20-014554-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-06-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019258/0001127602-20-019258-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052855/0001193125-20-052855-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052867/0001193125-20-052867-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520098977/0001193125-20-098977-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115068/0001193125-20-115068-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115084/0001193125-20-115084-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520135621/0001193125-20-135621-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520141579/0001193125-20-141579-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520157384/0001193125-20-157384-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520277496/0001193125-20-277496-index.htm
2010-05-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1492242/000149224210000001/0001492242-10-000001-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1492422/000156459020007350/0001564590-20-007350-index.htm
2020-04-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020019689/0001564590-20-019689-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020034763/0001564590-20-034763-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020049423/0001564590-20-049423-index.htm
2020-08-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1492422/999999999720004458/9999999997-20-004458-index.htm

Apellis Pharmaceuticals, Inc (APLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apellis Pharmaceuticals, Inc (APLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2117%
Institutional Ownership: 8285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-13Pascal DeschateletsChief Operating OfficerSell55,398.0040.982,270,154.641,008,681.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell5,000.0040.67203,330.001,027,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell30,637.0040.661,245,792.331,032,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell300.0023.867,158.001,053,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell3,212.0022.2871,556.941,053,367.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell15,065.0021.58325,087.641,056,579.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-02-19Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,058,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,063,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-13Pascal DeschateletsChief Operating OfficerBuy117,205.002.14250,818.701,064,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-10Cedric FrancoisChief Executive OfficerBuy34,375.001,066,805.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell12,060.0020.69249,557.581,071,644.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-10-15Cedric FrancoisChief Executive OfficerSell5,000.0034.46172,300.001,083,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-03-17Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell700.0022.2915,600.201,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,192.0021.5747,279.251,084,404.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,108.0020.7343,694.621,086,596.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-09-15Cedric FrancoisChief Executive OfficerSell5,000.0030.96154,800.001,088,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,088,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-08-20Cedric FrancoisChief Executive OfficerSell3,457.0030.00103,710.001,093,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-08-18Cedric FrancoisChief Executive OfficerSell1,543.0030.0046,290.001,096,536.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-07-15Cedric FrancoisChief Executive OfficerSell5,000.0032.12160,600.001,098,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-06-15Cedric FrancoisChief Executive OfficerSell5,000.0030.21151,050.001,103,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-05-15Cedric FrancoisChief Executive OfficerSell5,000.0029.92149,600.001,108,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-04-15Cedric FrancoisChief Executive OfficerSell5,000.0029.77148,850.001,113,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-02-10LUKAS SCHEIBLEROfficerBuy9,375.0012,310.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-10-07Victoria L. BrownProgram Team LeadBuy12,000.0018.98227,760.0015,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10Timothy Eugene SullivanChief Financial OfficerBuy11,688.0023,387.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-10Nicole D PerryVice President - FinanceBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-10Ahmad SadrOfficerBuy2,725.002,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-11-02Federico GrossiCHIEF MEDICAL OFFICERSell600.0031.0918,654.0027,725.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-10-01Federico GrossiOfficerSell600.0030.2218,132.0028,325.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-09-01Federico GrossiOfficerSell600.0031.5818,948.0028,925.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-08-03Federico GrossiOfficerSell600.0026.2815,768.0029,525.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-07-01Federico GrossiOfficerSell850.0032.4327,565.5030,125.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-06-15Federico GrossiOfficerSell856.0030.2125,859.7630,975.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-02-10Federico GrossiOfficerBuy9,375.0031,831.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-10David O. WatsonGeneral CounselSell5,000.0044.50222,500.0035,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-10-07Victoria L. BrownProgram Team LeadSell12,000.0035.00420,000.003,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10David O. WatsonGeneral CounselBuy6,375.0040,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-10David O. WatsonGeneral CounselBuy7,505.002.6720,038.3542,922.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-05-08PAUL R. FONTEYNEDirectorBuy5,000.0031.81159,034.005,000.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-02-10Lucia CelonaOfficerBuy5,213.005,213.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-14Alec MachielsDirectorSell2,500.0042.35105,875.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorSell2,500.0030.2175,525.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-07Alec MachielsDirectorSell7,500.0035.00262,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-15Alec MachielsDirectorSell2,500.0035.0087,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-02-14Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-10-07Alec MachielsDirectorBuy7,500.002.6720,025.00677,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-02-10Thomas A. LacknerOfficerBuy2,725.007,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-10Pascal DeschateletsChief Operating OfficerBuy9,375.00891,118.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-10Adam J. TownsendOfficerBuy9,375.009,375.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerSell52,075.0042.802,228,966.23946,874.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerBuy117,206.002.14250,820.84998,949.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm